A Modern CDMO for Early-Stage Antibody Companies

A Modern CDMO for Early-Stage Antibody Companies

Monday, April 15, 2024 5:10 PM to 5:30 PM · 20 min. (US/Pacific)
CMC & Developability, sponsored by Croda Pharma
Presentation
Room 4

Information

The team at Wheeler Bio, an antibody CDMO located in Oklahoma City, OK, spent the last three years standing up a purpose-built, boutique CDMO to better serve the needs of preclinical and clinical stage antibody companies needing early CMC development and cost-effective material supply services that better align with current fundraising challenges. With a digital-first approach to platform development that fully embraced modern bioprocess design, bioprocess modeling, machine learning, and integrated automations, Wheeler has built an open-source platform called Portable CMC® with proven scalability and cost-effectiveness. Efforts to integrate early CMC development with late discovery workflows have led to collaborative partnerships with coastal discovery CROs, including Alloy Therapeutics and Charles River Laboratories, that further distinguish Wheeler’s unique value proposition to biotechs. In this presentation, Dr. McNaull will share an overview of the platform development strategy and current performance metrics and describe how Wheeler better integrates programs from discovery to CMC development and early clinical supply.

Wheeler Bio832Wheeler Bio is a biomanufacturing pioneer founded by a team of industry experts and strategic investors who believe a different CDMO model is needed for innovators to bring new therapeutic leads to the clinic faster, without the risk and cost associated with traditional outsourcing models. Our novel hub-and-spoke concept, centered in Oklahoma City with satellite labs embedded in discovery centers on the coasts, will revolutionize the translational path from discovery to CMC development and first patient dosing. Wheeler’s pioneering, highly-accessible, open-source development platform – Portable CMC® – delivers speed to clinic and uniquely-affordable workflows by integrating discovery CROs and CDMOs. Portable CMC® is a suite-ready drug substance manufacturing platform that customers can transfer to any CDMO in the world with no royalties, licensing fees or penalties. By overlapping with the discovery workflow, Portable CMC® reduces timelines and regulatory risks through the introduction of QbD (Quality-by-Design) principles earlier on in the drug development life cycle, increasing the opportunity for clinical success.

Log in